Novavax Secures FDA Emergency Authorization For Adjuvanted Covid-19 Vaccine
The U.S. Food and Drug Administration (FDA) grants emergency use authorization (EUA) to Novavax’s (NASDAQ: NVAX) lead candidate Adjuvanted (NVX-CoV2373) COVID-19 Vaccine for individuals 18 years of age and over.
